Market Overview

How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program

How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program

Moderna Inc (NASDAQ: MRNA) shares came under significant selling pressure Thursday afternoon following an adverse patent ruling, and the stock is adding to the losses in Friday's session. 

Moderna Loses Patent Challenge: In an ongoing legal dispute, the Patent Trial and Appeal Board ruled against Moderna's challenge to the patentability of Arbutus Biopharma Corp's (NASDAQ: ABUS) ABUS'069 patent.

The ‘069 patent covers liquid nanoparticle formulations, or LNPs, meant for nucleic acid delivery, which is used by Moderna in its vaccine candidates.

The patent describes the composition of nucleic acid-lipid particles and the ranges in which the different lipid particle components can be combined for effective delivery of nucleic acid sequence payload.

Moderna holds four non-exclusive viral vaccine sublicenses of Arbutus-issued LNP delivery technology. Each one allows for the use of pre-April 15, 2010 LNP patent families and is limited to a specific viral target, Chardan analyst Keay Nakae said in a note. 

These sub-licenses would not be applicable to Moderna's mRNA-1273, the analyst said. 

Potential Impact On Moderna: The sell-side is in wait-and-watch mode as investors digest the development.

"This legal dispute has been an ongoing debate among investors, and today's decision is a disappointing turn for MRNA," said SVB Leerink analyst Mani Foroohar said in a note reviewing the development. The analyst initiated coverage of Moderna shares on Thursday. 

This could lead to a protracted period of investor controversy and debate around the implications of any potential infringement claims by Arbutus regarding Moderna's use of LNP delivery technology in its investigational vaccines, and any further actions Moderna may take to defend its own IP position, the analyst said. 

Discussions around the ruling will also involve IP and potential royalty/economic claims by Arbutus on Moderna, he said.

Foroohar sees any meaningful royalty burden as hampering Moderna's pricing flexibility and margin versus other players in the SARS-CoV-2 vaccine race.

This could potentially aggravate downside implications should a HCV-like competitive pricing dynamic emerge, the analyst said. 

"We continue to watch this emerging dynamic closely, but do not explicitly model any royalty burden, settlement or other financial impact in our MRNA model at this time." 

MRNA Price Action: At last check, Moderna shares were slipping by 7.22% to $72.13 after plunging about 10% Thursday.

Arbutus shares were down 7.9% at $5.71 at last check. 

Related Links:

The Week Ahead In Biotech: Jazz Awaits FDA Nod For Sleep Disorder Drug, Earnings Trickle In, ACell IPO

5 Coronavirus Stock Valuations Surging During The Pandemic

Latest Ratings for MRNA

Sep 2020SVB LeerinkDowngradesMarket PerformUnderperform
Aug 2020SVB LeerinkMaintainsMarket Perform
Aug 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for MRNA
View the Latest Analyst Ratings


Related Articles (MRNA)

View Comments and Join the Discussion!

Posted-In: Chardan Keay Nakae Mani FooraharAnalyst Color Biotech News Analyst Ratings General Best of Benzinga

Latest Ratings

PRGOSVB LeerinkMaintains63.0
NOWWells FargoMaintains565.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at